. 2023 Nov 7;38(45):e381. doi: 10.3346/jkms.2023.38.e381

Table 2. Stratified analysis of the associations between polymorphism and clinical outcomes according to stage.

Polymorphism	Stage	Genotype	No. of cases (%)^a	Response to chemotherapy				Overall survival			P _H
Polymorphism	Stage	Genotype	No. of cases (%)^a	Responders (%)^b	Nonresponders (%)^b	OR (95% CI)^c	P ^c	L-R-P	HR (95% CI)^d	P ^d	P _H
RNF145 rs2043268	LD	AA	24 (36.4)	17 (70.8)	7 (29.2)	1.00		0.005	1.00
		AG	27 (40.9)	20 (74.1)	7 (25.9)	0.84 (0.20–3.52)	0.810		0.69 (0.29–1.65)	0.409
		GG	15 (22.7)	9 (60.0)	6 (40.0)	0.47 (0.08–2.61)	0.386		2.46 (0.89–6.77)	0.082
		Dominant				0.70 (0.19–2.64)	0.598	0.513	0.96 (0.45–2.08)	0.921
		Recessive				0.52 (0.12–2.32)	0.389	0.001	3.17 (1.37–7.31)	0.007
		Codominant				0.70 (0.29–1.65)	0.408		1.54 (0.88–2.67)	0.129
	ED	AA	47 (24.6)	34 (72.3)	13 (27.7)	1.00		0.012	1.00
		AG	89 (46.6)	73 (82.0)	16 (18.0)	2.03 (0.83–4.99)	0.122		0.78 (0.53–1.17)	0.230	0.803
		GG	55 (28.8)	35 (63.6)	20 (36.4)	0.62 (0.25–1.50)	0.286		1.56 (1.03–2.36)	0.038	0.414
		Dominant				1.18 (0.54–2.55)	0.681	0.852	1.02 (0.72–1.47)	0.895	0.889
		Recessive				0.41 (0.20–0.87)	0.020	0.004	1.79 (1.26–2.55)	0.001	0.217
		Codominant				0.75 (0.47–1.21)	0.238		1.26 (1.00–1.58)	0.047	0.005
CINP rs762105	LD	AA	23 (35.9)	16 (69.6)	7 (30.4)	1.00		0.504	1.00
		AG	27 (42.2)	20 (74.1)	7 (25.9)	0.65 (0.12–3.60)	0.624		1.20 (0.52–2.81)	0.668
		GG	14 (21.9)	8 (57.1)	6 (42.9)	0.30 (0.05–1.89)	0.200		1.88 (0.74–4.79)	0.186
		Dominant				0.48 (0.10–2.32)	0.363	0.674	1.40 (0.63–3.10)	0.411
		Recessive				0.40 (0.09–1.67)	0.207	0.242	1.66 (0.80–3.41)	0.172
		Codominant				0.54 (0.21–1.36)	0.192		1.39 (0.86–2.22)	0.177
	ED	AA	49 (25.9)	42 (85.7)	7 (14.3)	1.00		0.024	1.00
		AG	87 (46.0)	59 (67.8)	28 (32.2)	0.34 (0.13–0.91)	0.032		2.56 (1.70–3.87)	< 0.001	0.116
		GG	53 (28.0)	39 (73.6)	14 (26.4)	0.50 (0.17–1.47)	0.208		2.21 (1.40–3.47)	< 0.001	0.760
		Dominant				0.40 (0.16–1.00)	0.051	0.007	2.42 (1.64–3.56)	< 0.001	0.225
		Recessive				1.07 (0.49–2.31)	0.869	0.508	1.24 (0.87–1.77)	0.235	0.476
		Codominant				0.77 (0.47–1.24)	0.285		1.44 (1.17–1.77)	< 0.001	0.892

LD = limited disease, ED = extensive disease, OR = odds ratio, CI = confidence interval, L-R-P = log-rank P, HR = hazard ratio, ECOG = Eastern Cooperative Oncology Group, NSE = neuron specific enolase.

^aColumn percentage.

^bRow percentage.

^cORs, 95% CI, and their corresponding P values were calculated by multivariate regression analysis, adjusted for age, sex, smoking status, stage, ECOG performance status, weight loss, NSE level, and first chemotherapy regimen.

^dHRs, 95% CI and their corresponding P values were calculated using multivariate Cox proportional hazard models, adjusted for age, sex, smoking status, stage, ECOG performance status, weight loss, NSE level, first chemotherapy regimen, 2^nd line chemotherapy and radiation to primary tumor.